Journal of Alzheimer's Disease


Publication Venue For

  • Dementia Care in Diverse Older Adults in the U.S. Deep South and the Rest of the United States.  83:1753-1765. 2021
  • Racial Differences in Alzheimer's Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2.  79:543-557. 2021
  • Relationships between Chronic Pain Stage, Cognition, Temporal Lobe Cortex, and Sociodemographic Variables.  80:1539-1551. 2021
  • Mid- And Late-Life Leisure-Time Physical Activity and Global Brain Amyloid Burden- And Atherosclerosis Risk in Communities (ARIC)-PET Study.  76:139-147. 2020
  • Ozone and Particulate Matter Exposure and Alzheimer's Disease: A Review of Human and Animal Studies.  76:807-824. 2020
  • Pro-Neurotensin/Neuromedin N and Risk of Cognitive Impairment in a Prospective Study.  76:1403-1412. 2020
  • Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative.  76:691-701. 2020
  • Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications.  70:1241-1257. 2019
  • Dementia Risk Elevates Brain Activity During Memory Retrieval: A Functional MRI Analysis of Middle Aged and Older Adults.  70:1005-1023. 2019
  • A Small Molecule Inhibitor of Plasminogen Activator Inhibitor-1 Reduces Brain Amyloid-β Load and Improves Memory in an Animal Model of Alzheimer's Disease.  64:447-457. 2018
  • No effects of black tea on cognitive decline among older US men: A prospective cohort study.  65:99-105. 2018
  • Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review.  57:29-36. 2017
  • White Matter Degradation is Associated with Reduced Financial Capacity in Mild Cognitive Impairment and Alzheimer's Disease.  60:537-547. 2017
  • N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the REGARDS Cohort.  54:497-503. 2016
  • Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials.  50:1205-1215. 2016
  • An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia.  53:393-402. 2016
  • In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-β pathology.  36:335-347. 2013
  • Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice.  34:609-620. 2013
  • Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of alzheimer's disease.  30:943-961. 2012
  • Anti-amyloid-β single-chain antibody brain delivery via aav reduces amyloid load but may increase cerebral hemorrhages in an alzheimer's disease mouse model.  27:23-28. 2011
  • Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease.  26:767-778. 2011
  • Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology.  24:301-313. 2011
  • Lesion-induced hippocampal plasticity in transgenic alzheimer's disease mouse models: Influences of age, genotype, and estrogen.  18:429-445. 2009
  • Vascular endothelial barrier dysfunction mediated by amyloid-β proteins.  17:845-854. 2009
  • Distractibility and Alzheimer disease: The "neglected" phenomenon.  15:1-10. 2008